Immunotherapy, a revolutionary approach to cancer treatment, is transforming the oncological landscape. As physicians, understanding the intricacies of these therapies is imperative to ensure optimal patient care.
Immunotherapy harnesses the body's immune system to fight cancer. It does this in two ways: by stimulating the immune system to work harder or by providing it with artificial immune system proteins. The main types include checkpoint inhibitors, CAR T-cell therapy, and cancer vaccines.
These drugs, such as pembrolizumab and nivolumab, block immune checkpoints, proteins that prevent immune cells from attacking non-harmful cells in the body. By doing so, they boost the immune response against cancer cells.
Chimeric Antigen Receptor (CAR) T-cell therapy involves modifying a patient's T cells to express a specific receptor that can bind to a certain protein on cancer cells, enhancing the immune system's ability to target and destroy these cells.
Cancer vaccines, like the Sipuleucel-T for prostate cancer, work by stimulating the immune system to attack specific cancer cells. These vaccines can be either preventive, like the HPV vaccine, or therapeutic, like the Bacillus Calmette-Guérin (BCG) vaccine for bladder cancer.
Immunotherapy can cause side effects, often resembling flu-like symptoms. However, severe immune-mediated adverse events can occur. Physicians must be adept at recognizing these and managing them effectively, often requiring multidisciplinary collaboration.
Immunotherapy represents a significant shift in cancer treatment, offering new hope to patients. As physicians, it is crucial to stay updated on these therapies, their mechanisms of action, and their management to provide the best possible care to our patients.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation